ISLAMABAD – Over two dozen patients in Islamabad get counterfeit Flu vaccines, which prompted to arrest of Lab owner along with two officials.
The disturbing case of alleged medical fraud surfaced in capital, where Excel Lab is accused of administering counterfeit and substandard flu vaccines to unsuspecting patients. The scandal triggered serious questions about patient safety, the authenticity of imported medicines and oversight of private healthcare facilities.
Federal Investigation Agency (FIA) has arrested three individuals, including the chief executive officer (CEO) of a private laboratory, after investigators uncovered evidence suggesting that at least 26 patients had received allegedly counterfeit flu vaccine injections.
The arrests followed a joint operation by the FIA’s Anti-Corruption Circle Islamabad and a drug inspector at a laboratory situated in the capital’s busy Blue Area.
During the raid, officials reportedly seized 27 injections suspected of containing counterfeit influenza vaccines, raising concerns about how such medical products allegedly reached patients through a healthcare facility.
The arrested suspects were produced before Judicial Magistrate Shaista Kundi on Friday, where the FIA sought 14 days of physical custody to investigate the suspected vaccine fraud. The suspects included the laboratory’s CEO, marketing manager and assistant manager.
Investigators argued that further interrogation was necessary to establish the source of the suspected counterfeit injections, examine their distribution and determine the possible involvement of other individuals. The magistrate granted FIA five days of physical remand, allowing investigators to continue questioning the suspects while examining the evidence recovered during the operation.
Excel Labs CEO among three Arrested in Islamabad Fake Flu Vaccine Crackdown
One of key most alarming revelations presented during the proceedings concerned origin of vaccines allegedly administered to patients. According to the FIA, the laboratory had been using injections marketed as Influvac Tetra, a flu vaccine, carrying lot number P13.
The agency informed the court that reports from Drug Regulatory Authority of Pakistan (DRAP) and the Punjab government had identified the specified vaccine lot as counterfeit and substandard. Investigators further claimed that the particular batch had never been legally imported into Pakistan, raising serious questions about where the injections originated and how they reached the laboratory.
The alleged absence of an official import record has made the vaccine’s supply chain a central focus of the investigation.
The investigation took another troubling turn when authorities reportedly recovered records indicating that the suspected counterfeit vaccines had already been administered to 26 patients. Among those listed was the daughter of the complainant, whose complaint forms part of the case.
Although investigators alleged that counterfeit vaccines were administered, the available case details do not establish whether any of the affected patients suffered adverse health consequences.


















